Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease. In randomized, controlled trials, oral rasagiline 1 mg once daily was superior to placebo in the symptomatic treatment of early Parkinson's disease, both as monotherapy or as an adjunct to dopamine agonists. Comparisons of early-start and delayed-start treatment suggested a disease-modifying effect for rasagiline, but the results were equivocal. Rasagiline 0.5 or 1 mg/day was also superior to placebo as adjunctive therapy to levodopa in Parkinson's disease patients with motor fluctuations. Rasagiline was generally well tolerated in clinical trials, displaying a placebo-like tolerability profile in several studies. Cost-utility studies predicted that rasagiline, either as monotherapy or adjunctive therapy, would be a cost-effective treatment option. Therefore, oral rasagiline is a valuable therapeutic option for use in all stages of Parkinson's disease.

译文

雷沙吉兰 (Azilect (®)) 是一种口服,第二代,选择性,不可逆的单胺氧化酶-B (mao-b) 抑制剂,在美国被批准用于治疗帕金森氏病。在随机对照试验中,口服雷沙吉兰1 mg,每日一次,在对早期帕金森氏病的对症治疗方面优于安慰剂,无论是作为单药治疗还是作为多巴胺激动剂的辅助治疗。早期开始和延迟开始治疗的比较表明雷沙吉兰具有改善疾病的作用,但结果模棱两可。在运动波动的帕金森氏病患者中,雷沙吉兰0.5或1 mg/天也优于安慰剂作为左旋多巴的辅助治疗。雷沙吉兰在临床试验中通常耐受性良好,在多项研究中显示出类似安慰剂的耐受性。成本效用研究预测,雷沙吉兰作为单一疗法或辅助疗法,将是一种具有成本效益的治疗选择。因此,口服雷沙吉兰是用于帕金森氏病所有阶段的有价值的治疗选择。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录